Introduction:Basic information about CAS 379270-38-9|GS-7340 (fumarate), including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | GS-7340 (fumarate) |
|---|
| CAS Number | 379270-38-9 | Molecular Weight | 592.538 |
|---|
| Density | / | Boiling Point | / |
|---|
| Molecular Formula | C25H33N6O9P | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
| Name | Tenofovir alafenamide fumarate |
|---|
| Synonym | More Synonyms |
|---|
GS-7340 (fumarate) BiologicalActivity
| Description | Tenofovir alafenamide fumarate (GS-7340 fumarate) is an investigational oral prodrug of Tenofovir. Tenofovir is a HIV-1 nucleotide reverse transcriptase inhibitor. |
|---|
| Related Catalog | Signaling Pathways >>Anti-infection >>HIVSignaling Pathways >>Anti-infection >>Reverse TranscriptaseResearch Areas >>Infection |
|---|
| Target | HIV-1, NRTIs[1] |
|---|
| In Vitro | Tenofovir alafenamide antiviral activities are similar across all cell types, ranging from 5 to 7 nM, while the CC50 varies from 4.7 to 42 μM for MT-4 and MT-2 cells, respectively. The antiviral activity of TAF is evaluated against a panel of HIV-1 and HIV-2 isolates, including HIV-1 group M subtypes A to G, as well as group N and O isolates. Overall, for the 29 primary HIV-1 isolates tested in PBMCs, TAF EC50s range from 0.1 to 12 nM, with a mean EC50 of 3.5 nM compared to a mean EC50 of 11.8 nM for AZT, which is used as an internal control. For the HIV-2 isolates, the mean EC50s are 1.8 nM for TAF and 6.4 nM for AZT[2]. |
|---|
| In Vivo | Tenofovir alafenamide hemifumarate is an amidate prodrug of Tenofovir with good oral bioavailability and increases plasma stability compared to Tenofovir disoproxil fumarate (TDF)[1]. |
|---|
| References | [1]. Babusis D, et al. Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340. Mol Pharm. 2013 Feb 4;10(2):459-66. [2]. Ruane PJ, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):449-55. |
|---|
Chemical & Physical Properties
| Molecular Formula | C25H33N6O9P |
|---|
| Molecular Weight | 592.538 |
|---|
| Exact Mass | 592.204651 |
|---|
| PSA | 227.89000 |
|---|
| LogP | 3.65680 |
|---|
| InChIKey | MEJAFWXKUKMUIR-UHFFFAOYSA-N |
|---|
| SMILES | CC(C)OC(=O)C(C)NP(=O)(COC(C)Cn1cnc2c(N)ncnc21)Oc1ccccc1.O=C(O)C=CC(=O)O |
|---|
| Storage condition | 2-8℃ |
|---|
Synonyms
| Tenofovir alafenamide fumarate, 1:1 |
| TAF |
| GS-7340 fumarate |
| Isopropyl N-[(S)-({[(2R)-1-(6-amino-9H-purin-9-yl)-2-propanyl]oxy}methyl)(phenoxy)phosphoryl]-L-alaninate (2E)-2-butenedioate (1:1) |
| L-Alanine, N-[(S)-[(1S)-[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester, (2E)-2-butenedioate (1:1) |
| Tenofovir alafenamide fumarate1:1 |
| GS-7340 (fumarate) |